Rationale: Trace amine-associated receptor 1 (TAAR1) is the best-studied receptor of trace amines, a group of biogenic amines expressed at a relatively low level in the mammalian brain. Growing evidence suggests that TAAR1 plays a critical role in various neuropsychiatric disorders. Given that selective TAAR1 agonists were shown to produce pro-cognition and antipsychotic-like effects as well as to suppress drug use and relapse, they have been proposed to be novel treatments for mental disorders such as schizophrenia and addiction. However, the aversive effects of selective TAAR1 agonists remain largely unknown.
Objectives: Here, we evaluated whether the selective TAAR1 full agonist RO5166017 and partial agonist RO5263397 could induce conditioned taste aversion (CTA).
Results: We found that RO5166017 and RO5263397 produced significant aversions to both saccharin and NaCl taste novelty. Furthermore, RO5166017 produced CTA to saccharin in TAAR1 heterozygous knockout (taar1) and wild-type rats but not in TAAR1 homozygous knockout rats (taar1), suggesting that TAAR1 was sufficient for the taste aversive stimulus property of RO5166017.
Conclusions: Taken together, our data indicate that selective TAAR1 agonists could produce strong CTA. Our study urges careful evaluations of the aversive effects of TAAR1 agonists before translating them to clinical use for the treatment of mental disorders.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00213-022-06222-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unlocking the secrets of trace amine-associated receptor 1 agonists: new horizon in neuropsychiatric treatment.
Front Psychiatry
October 2024
Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.
For over seven decades, dopamine receptor 2 (D receptor) antagonists remained the mainstay treatment for neuropsychiatric disorders. Although it is effective for treating hyperdopaminergic symptoms, it is often ineffective for treating negative and cognitive deficits. Trace amine-associated receptor 1 (TAAR1) is a novel, pharmacological target in the treatment of schizophrenia and other neuropsychiatric conditions.
View Article and Find Full Text PDFMolecular Mechanisms of Methamphetamine-Induced Addiction via TAAR1 Activation.
J Med Chem
October 2024
Tianjin Key Laboratory of Function and Application of Biological Macromolecular Structures, School of Life Sciences, Tianjin University, 92 Weijin Road, Nankai District, Tianjin 300072, China.
Article Synopsis
- The study focuses on the trace amine-associated receptor 1 (TAAR1), which recognizes trace amines like β-phenylethylamine and methamphetamine in the brain and is linked to disorders such as schizophrenia and substance abuse.
- Researchers determined the structure of the human TAAR1-G protein complex with methamphetamine and explored how TAAR1 selectively binds to different ligands through functional studies and molecular dynamics simulations.
- The findings highlight a hydrophobic core in the receptor's transmembrane helices that activates TAAR1, providing insights for developing new treatments for substance abuse and various neurological disorders.
TAAR1 and 5-HT receptor agonists attenuate autism-like irritability and aggression in rats prenatally exposed to valproic acid.
Pharmacol Biochem Behav
December 2024
Sumitomo Pharma America, Inc., Marlborough, MA, USA. Electronic address:
Despite the rising prevalence of autism spectrum disorder (ASD), there remains a significant unmet need for pharmacotherapies addressing its core and associative symptoms. While some atypical antipsychotics have been approved for managing associated irritability and aggression, their use is constrained by substantial side effects. This study aimed firstly to develop behavioral measures to explore frustration, irritability and aggression phenotypes in the rat prenatal valproic acid (VPA) model of ASD.
View Article and Find Full Text PDFHIV-1 and methamphetamine co-treatment in primary human astrocytes: TAARgeting ER/UPR dysfunction.
NeuroImmune Pharm Ther
June 2024
Department of Microbiology, Immunology and Genetics at University of North Texas Health Science Center, Fort Worth, TX, 76107, USA.
Objectives: Human immunodeficiency virus 1 (HIV-1) can invade the central nervous system (CNS) early during infection and persist in the CNS for life despite effective antiretroviral treatment. Infection and activation of residential glial cells lead to low viral replication and chronic inflammation, which damage neurons contributing to a spectrum of HIV-associated neurocognitive disorders (HAND). Substance use, including methamphetamine (METH), can increase one's risk and severity of HAND.
View Article and Find Full Text PDFIs there a role for biogenic amine receptors in mediating β-phenylethylamine and RO5256390-induced vascular contraction?
Eur J Pharmacol
October 2024
Division of Pharmacology, School of Pharmacy, Cardiff University, Cardiff, United Kingdom.
Article Synopsis
- Trace amines can cause blood vessel constriction without involving noradrenaline, and the exact mechanism behind this is still unclear.
- The study tested the effects of β-phenylethylamine (β-PEA) and a TAAR1-selective agonist on blood vessel constriction in rat aortic rings and mesenteric arteries.
- Results showed that vasoconstriction in aortic rings was not affected by common biogenic amine antagonists, suggesting TAAR1 is likely responsible for the response to trace amines.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!